← All trials
NCT05093829
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2022
- Primary completion
- Dec 31, 2023
- Completion date
- Jul 31, 2025
- First posted
- Oct 26, 2021
- Last posted
- Oct 26, 2021
- Enrollment
- 1320
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Emory UniversityLead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- University of MarylandReponsible party - principal investigator
- University of MarylandStudy chair
- University of MarylandStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.